R-Roscovitine simultaneously targets both the p53 and NF-κB pathways and causes potentiation of apoptosis: Implications in cancer therapy

Cell Death and Differentiation

Volumn 15, Issue 2, 2008, Pages 263-273

  Dey, A ^a   Wong, E T ^b   Cheok, C F ^a   Tergaonkar, V ^b   Lane, D P ^a  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b Laboratory of NF KB Signaling in Human Ailments

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 8; PROTEIN P53; ROSCOVITINE; SERINE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INTERLEUKIN-1; NEOPLASM PROTEINS; NF-KAPPA B; PHOSPHORYLATION; PURINES; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38149082690     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402257     Document Type: Article

References (40)

1. Webster GA, Perkins ND, Transcriptional cross talk between NF-kappaB and p53. Mol Cell Biol 1999; 19: 3485-3495.
2. Vogelstein B, Lane D. Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
3. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
4. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007; 8: 49-62.
5. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: How hot is the link? Biochem Pharmacol 2006; 72: 1605-1621.
6. Tergaonkar V. NFkappaB pathway: A good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 2006; 38: 1647-1653.
7. Gilmore TD, Herscovitch M. Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 2006, 25: 6887-6899.
8. Maccallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella-Borradori A et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005: 65: 5399-5407.
9. Lu W, Chen Peng Y, Chen J. Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene 2001, 20: 3206-3216.
10. Rubbi CP, Milner J. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J 2003; 22: 6068-6077.
11. Whittaker SR, Walton MI, Garrett MD, Workman P. The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway. Cancer Res 2004; 64 262-272.
12. Crescenzi E, Palumbo G, Brady HJ. Roscovitine modulates DNA repair and senescence: Implications for combination chemotherapy. Clin Cancer Res 2005; 11: 8158-8171.
13. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002; 102: 463-468.
14. Raynaud Fl, Whittaker SR, Fischer PM, McClue S, Walton MI, Barrie SE et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 2005; 11: 4875-4887.
15. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005; 106: 1042-1047.
16. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005; 105: 4484-4491.
17. Monaco III EA, Beaman-Hall CM, Mathur A, Vallano ML. Roscovitine, olomoucine, purvalanol: Inducers of apoptosis in maturing cerebellar granule neurons. Biochem Pharmacol 2004; 67: 1947-1964.
18. Rossi AG. Sawatzky DA, Walker A, Ward C, Sheldrake TA, Riley NA et al Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 2006; 12: 1056-1064.
19. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006; 444: 949-952.
20. Baeuerle PA, Baichwal VR. NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 1997; 65: 111-137.
21. Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 1998; 17: 1045-1052.
22. Aggarwal BB. Nuclear factor-kappaB: The enemy within. Cancer Cell 2004; 6: 203-208.
23. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19 5785-5799.
24. Yamamoto K, Arakawa T, Ueda N, Yamamoto S. Transcriptional roles of nuclear factor kappa B and nuclear factor-interleukin-6 in the tumor necrosis factor alpha-dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. J Biol Chem 1995; 270: 31315-31320.
25. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-6866.
26. Osborn L. Kunkel S, Nabel GJ. Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B. Proc Natl Acad Sci USA 1989; 86: 2336-2340.
27. Miyamoto S, Maki M, Schmitt MJ, Hatanaka M, Verma IM. Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci USA 1994; 91: 12740-12744.
28. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1: 661-671.
29. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787.
30. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007, 96: 29-37.
31. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.
32. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004; 64: 3653-3660.
33. Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-2978.
34. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: Abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004; 279: 4750-4759.
35. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ et al. Nuclear factor-kappaB (nf-kappaB) is frequenfly expressed in lung cancer and preneoplastic lesions. Cancer 2006; 107(11): 2637-2646.
36. Li J, Joo SH, Tsai MD. An NF-kappaB-specific inhibitor, IkappaBalpha, binds to and inhibits cyclin-dependent kinase 4. Biochemistry 2003; 42: 13476-13483.
37. Komarova EA, Krivokrysenko V, Wang K, Neznanov N, Chernov MV, Komarov PG et al. p53 is a suppressor of inflammatory response in mice. FASEB J 2005; 19: 1030-1032.
38. Gurova KV, Hill JE, Guo C, Prokvolft A, Burdelya LG, Samoylova E et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005: 102: 17448-17453.
39. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkappaB kinase-independent IkappaBalpha degradation pathway: Functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003; 23: 8070-8083.
40. O'Hagan HM, Ljungman M. Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene 2004; 23: 5505-5512.